Method for treating tumor by using recombinant interferon with changed spatial configuration

Abstract

The present invention provides methods for treating tumors in subjects by using a recombinant interferon (rSIFN-co), and optionally, methods for treating solid tumors, such as lung cancer, among others, with or without prior surgery, and as a first line or second line monotherapy or in combination with one or more other anti-tumor therapies. The present invention further provides non-surgical methods for eliminating tumors or reducing tumor sizes in subjects, and/or preventing postoperative tumor recurrence and/or metastases in subjects by using the recombinant interferon (rSIFN-co) which comprises a unique spatial configuration, alone or in conjunction with radiotherapy, chemotherapy, and/or one or more anti-tumor drugs such as biological agents, targeted drugs, small molecules, Traditional Chinese Medicine (TCM) and the like.

1 - 507 . (canceled) 
     
     
         508 . A method for eliminating or reducing the malignant pleural effusion, malignant ascites, and/or malignant pericardial effusion in a subject with tumor, comprising administering to the subject a recombinant interferon encoded by SEQ ID NO: 2, wherein the recombinant interferon is administered in an amount in a range of about 30 μg to about 2000 μg by one administration. 
     
     
         509 . The method of  claim 508 , wherein the tumor is a solid tumor. 
     
     
         510 . The method of  claim 508 , wherein the recombinant interferon is administered to the subject by an administration route, the administration route comprises one or more of: infiltration administration, intrapleural administration, abdominal administration, pericardial administration, thoracic administration and intraperitoneal administration. 
     
     
         511 . The method of  claim 510 , wherein the recombinant interferon is additionally administered to the subject by systemic administration. 
     
     
         512 . The method of  claim 508 , wherein the subject is administered with at least one other anti-cancer drug. 
     
     
         513 . The method of  claim 512 , wherein said other anti-cancer drug is selected from the group consisting of chemotherapeutic drug, targeted drug, and biological drug. 
     
     
         514 . A method for preventing tumor recurrence or metastasis, or prolonging or maintaining a tumor-free status in a subject with a tumor, comprising administering to said subject a recombinant interferon encoded by the nucleotide sequence SEQ ID NO: 2, wherein said subject has been treated with at least one anti-cancer therapy before the administration of said recombinant interferon. 
     
     
         515 . The method of  claim 514 , wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy. 
     
     
         516 . The method of  claim 514 , wherein the recombinant interferon is administered to the subject by at least one of: systemic administration, local administration, and topical administration. 
     
     
         517 . The method of  claim 516 , wherein said recombinant interferon is administered to said subject in a single dose of the range of about 2 μg to about 2000 μg. 
     
     
         518 . A method for treating tumor in a subject, comprising topically or locally administering to the tumor lesions of the subject a recombinant interferon encoded by SEQ ID NO: 2. 
     
     
         519 . The method of  claim 518 , wherein the tumor lesions comprise metastatic tumor lesions. 
     
     
         520 . The method of  claim 518 , wherein the tumor lesions comprise at least one of: bone lesions, muscular lesions, subcutaneous tissue lesions, prostatic lesions and lymph node lesions. 
     
     
         521 . The method of  claim 519 , the tumor metastatic lesions comprise at least one of: bone metastatic lesions, muscular metastatic lesions, subcutaneous tissue metastatic lesions, prostatic metastatic lesions, and lymph node metastatic lesions. 
     
     
         522 . The method of  claim 518 , wherein the recombinant interferon is administered to the lesion by an administration route, the administration route comprises at least one of: infiltration administration, percutaneous administration, transdermal administration, epidermal administration and transmucosal administration. 
     
     
         523 . The method of  claim 518 , wherein the recombinant interferon is administered topically. 
     
     
         524 . The method of  claim 518 , wherein the recombinant interferon is administered by spraying. 
     
     
         525 . The method of  claim 518 , wherein the recombinant interferon is further administered systemically. 
     
     
         526 . The method of  claim 518 , wherein the subject is administered at least one other anti-cancer therapy. 
     
     
         527 . The method of  claim 526 , wherein said anti-cancer therapy is selected from the group consisting of chemotherapy, radiotherapy, surgical therapy, interventional therapy, biotherapy, gene therapy, ablation therapy, immunotherapy, targeted therapy, and traditional Chinese medicine therapy.